NEW YORK (GenomeWeb News) – Molecular diagnostics company Response Genetics said today that it has tapped the Australian firm Genetic Technologies to distribute three of its oncology testing panels in Southeast Asia and in Australia.
The agreement makes Genetic Technologies the exclusive distributor for the three ResponseDX tests, including the Colon, Lung, and Gastric genetic panels, in Australia, Indonesia, Malaysia, the Philippines, Singapore, and Thailand.
The ResponseDX tests are PCR-based and they analyze gene expression in tumors that correlate with common chemotherapy drugs.
"Based on encouraging sales and rapid adoption here in the Unites States, we have embarked on a growth strategy focused on expanding the availability of our tests in additional markets," Response Genetics CEO Kathleen Danenberg said in a statement.
All of Los Angeles-based Response Genetics' tests are performed through its CLIA-certified lab, and through clinical reference lab NeoGenomics Laboratories.